The safety profile was much the same in each group , although drug-related adverse events were more common with losmapimod 75 mg ( n = 19 , 13 % ) and losmapimod 15 mg ( n = 20 , 13 % ) than with placebo ( n = 11 , 7 % ) and losmapimod 25 mg ( n = 13 , 9 % ) .